“MGH researchers and clinicians continue to make unprecedented progress for patients as they develop novel cell and gene therapies,” said Peter L. Slavin, MD, president of the MGH.
“This collaboration with ElevateBio will enable us to amplify our efforts in the development and manufacture of cell and gene therapies.”
"At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio— a company so well positioned to change the face of cell and gene therapy forever— is a natural fit into our overall vision,” said David Williams, MD, the hospital’s chief of hematology/oncology. “Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s."
Meet the scientists and operators that bring decades of shared knowledge to the development of life transforming cell and gene therapies. Their knowhow moves potential product candidates from concept to commercialization.
